ursodeoxycholic acid

Summary

Summary: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.

Top Publications

  1. Azzaroli F, Raspanti M, Simoni P, Montagnani M, Lisotti A, Cecinato P, et al. High doses of ursodeoxycholic acid up-regulate the expression of placental breast cancer resistance protein in patients affected by intrahepatic cholestasis of pregnancy. PLoS ONE. 2013;8:e64101 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) administration in intrahepatic cholestasis of pregnancy (ICP) induces bile acids (BA) efflux from the foetal compartment, but the molecular basis of this transplacental transport is only partially defined.
  2. Leung J, Bonis P, Kaplan M. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2011;9:776-80 pubmed publisher
    The combination of ursodeoxycholic acid (UDCA), colchicine, and methotrexate (MTX) is effective therapy for a subset of patients with primary biliary cirrhosis (PBC) who do not respond to UDCA...
  3. Halilbasic E, Fiorotto R, Fickert P, Marschall H, Moustafa T, Spirli C, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology. 2009;49:1972-81 pubmed publisher
    24-norursodeoxycholic acid (norUDCA), a side chain-modified ursodeoxycholic acid derivative, has dramatic therapeutic effects in experimental cholestasis and may be a promising agent for the treatment of cholestatic liver diseases...
  4. Yang J, Kim J, Jeon J, Park H, Kang G, Park K, et al. Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS ONE. 2010;5:e13858 pubmed publisher
    ..It was recently reported that intraperitoneal administration of taurine-conjugated ursodeoxycholic acid (TUDCA) improved hepatic steatosis in ob/ob mice...
  5. Hohenester S, Oude Elferink R, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31:283-307 pubmed publisher
    ..b>Ursodeoxycholic acid (UDCA) is currently the only FDA-approved medical treatment for PBC...
  6. Hirschfield G, Heathcote E, Gershwin M. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology. 2010;139:1481-96 pubmed publisher
    ..These discoveries will hopefully lead to new therapeutic approaches for patients with cholestatic liver disease. ..
  7. Martínez Moya P, Romero Calvo I, Requena P, Hernández Chirlaque C, Aranda C, Gonzalez R, et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 2013;15:372-80 pubmed publisher
    ..Thus, although deoxycholic acid is regarded as a proinflammatory agent ursodeoxycholic acid, which is currently being used to treat certain types of cholestasis and primary biliary cirrhosis, because ..
  8. Kawata K, Kobayashi Y, Souda K, Kawamura K, Sumiyoshi S, Takahashi Y, et al. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. Antioxid Redox Signal. 2010;13:259-68 pubmed publisher
    The cytoprotective mechanisms of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) have not been fully clarified. UDCA has some antioxidant properties...
  9. Carotti S, Guarino M, Cicala M, Perrone G, Alloni R, Segreto F, et al. Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterol Motil. 2010;22:866-73, e232 pubmed publisher
    ..b>Ursodeoxycholic acid (UDCA) restores GB contractility and antagonises liver macrophage activation...

More Information

Publications62

  1. Ji W, Qu Q, Jin Y, Zhao L, He X. [Ursodeoxycholic acid inhibits hepatocyte-like cell apoptosis by down-regulating the expressions of Bax and Caspase-3]. Zhonghua Yi Xue Za Zhi. 2009;89:2997-3001 pubmed
    To investigate the mechanism of ursodeoxycholic acid (UDCA) in hepatocyte apoptosis using differentiated hepatocytes derived from bone marrow mesenchymal cells...
  2. Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism. 2012;61:944-53 pubmed publisher
    ..b>Ursodeoxycholic acid (UDCA) is widely used for the treatment of liver dysfunction...
  3. Dilger K, Hohenester S, Winkler Budenhofer U, Bastiaansen B, Schaap F, Rust C, et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol. 2012;57:133-40 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) exerts anticholestatic, antifibrotic and antiproliferative effects in primary biliary cirrhosis (PBC) via mechanisms not yet fully understood...
  4. Marciniak B, Kimber Trojnar Z, Leszczynska Gorzelak B, Patro Małysza J, Trojnar M, Oleszczuk J. [Treatment of obstetric cholestasis with polyunsaturated phosphatidylcholine and ursodeoxycholic acid]. Ginekol Pol. 2011;82:26-31 pubmed
    ..Polyunsaturated phosphatidylcholine (PPC) treatment was used in I group, ursodeoxycholic acid (UDCA) in II group and combination of them in III group...
  5. Takeuchi Y, Ikeda F, Fujioka S, Takaki T, Osawa T, Yasunaka T, et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol. 2011;26:1395-401 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) has been widely used in the treatment of patients with primary biliary cirrhosis (PBC). However, some patients are refractory to UDCA...
  6. Kim K, Jeong S, Lee J, Yeon J, Lee H, Kwon S, et al. [Clinical features and prognosis of primary biliary cirrhosis in Korea]. Korean J Hepatol. 2010;16:139-46 pubmed publisher
    ..5, and the Child-Pugh class was A, B, and C in 79%, 19%, and 2% of the patients, respectively. Ursodeoxycholic acid (UDCA) was used for treatment in 88% of the patients, among which 70% exhibited biochemical responses ..
  7. Lindor K, Kowdley K, Luketic V, Harrison M, McCashland T, Befeler A, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808-14 pubmed publisher
    Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC)...
  8. Kuiper E, Hansen B, de Vries R, den Ouden Muller J, van Ditzhuijsen T, Haagsma E, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281-7 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) improves laboratory liver test results in patients with primary biliary cirrhosis (PBC). Few studies have assessed the prognostic significance of biochemical data collected following UDCA treatment...
  9. Woo S, Kim J, Yu H. Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model. J Ocul Pharmacol Ther. 2010;26:223-9 pubmed publisher
    The aim of this study was to investigate the suppressing effects of systemically administered ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) on choroidal neovascularization (CNV) in a laser-treated rat model...
  10. Amaral J, Viana R, Ramalho R, Steer C, Rodrigues C. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50:1721-34 pubmed publisher
    ..Strikingly, hydrophilic ursodeoxycholic acid (UDCA), and its taurine-conjugated form (TUDCA), show profound cytoprotective properties...
  11. Rodriguez Ortigosa C, Banales J, Olivas I, Uriarte I, Marin J, Corrales F, et al. Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology. 2010;52:667-77 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) induces bicarbonate-rich hypercholeresis by incompletely defined mechanisms that involve the stimulation of adenosine triphosphate (ATP) release from cholangiocytes...
  12. Esmaily H, Vaziri Bami A, Miroliaee A, Baeeri M, Abdollahi M. The correlation between NF-?B inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol. 2011;25:723-33 pubmed publisher
    ..Anti-inflammatory effects of silibinin and ursodeoxycholic acid (UDCA) along with their NF-?B inhibitory property are thought to be beneficial in colitis...
  13. Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2012;10:CD000222 pubmed publisher
    ..One therapeutic option currently used is ursodeoxycholic acid. To analyse evidence that ursodeoxycholic acid improves indices of liver function, reduces the risk of ..
  14. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr. 2009;48:587-96 pubmed publisher
    ..was no difference in patients treated with pioglitazone combined with vitamin E versus vitamin E alone, ursodeoxycholic acid (UDCA) combined with vitamin E or alone versus placebo, or UDCA versus combination of vitamin E and vitamin ..
  15. Sinakos E, Marschall H, Kowdley K, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology. 2010;52:197-203 pubmed publisher
    High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates of serious adverse ..
  16. Paumgartner G. Pharmacotherapy of cholestatic liver diseases. J Dig Dis. 2010;11:119-25 pubmed publisher
    ..b>Ursodeoxycholic acid protects the biliary epithelium by reducing the toxicity of bile, stimulates hepatobiliary secretion by ..
  17. Kuiper E, Hansen B, Adang R, van Nieuwkerk C, Timmer R, Drenth J, et al. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2010;22:1495-502 pubmed publisher
    ..Age, male sex, cirrhosis, and portal hypertension are reported risk factors. It has been suggested that ursodeoxycholic acid (UDCA) may protect against HCC...
  18. Wiemuth D, Sahin H, Lefèvre C, Wasmuth H, Grunder S. Strong activation of bile acid-sensitive ion channel (BASIC) by ursodeoxycholic acid. Channels (Austin). 2013;7:38-42 pubmed publisher
    ..Furthermore, we show that rBASIC is strongly activated by the anticholestatic bile acid ursodeoxycholic acid (UDCA), suggesting that BASIC might mediate part of the therapeutic effects of UDCA.
  19. Saeki T, Yui S, Hirai T, Fujii T, Okada S, Kanamoto R. Ursodeoxycholic acid protects colon cancer HCT116 cells from deoxycholic acid-induced apoptosis by inhibiting apoptosome formation. Nutr Cancer. 2012;64:617-26 pubmed publisher
    We previously demonstrated that ursodeoxycholic acid (UDC) requires prolonged (?5 h) preincubation to exhibit effective protection of colon cancer HCT116 cells from deoxycholic acid (DC)-induced apoptosis...
  20. Chappell L, Gurung V, Seed P, Chambers J, Williamson C, Thornton J. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ. 2012;344:e3799 pubmed publisher
    To test whether ursodeoxycholic acid reduces pruritus in women with intrahepatic cholestasis of pregnancy, whether early term delivery does not increase the incidence of caesarean section, and the feasibility of recruiting women with ..
  21. Poupon R. Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates. Dig Dis. 2011;29:85-8 pubmed publisher
    Long-term treatment with ursodeoxycholic acid (UDCA; 13-15 mg/kg/day) in patients with primary biliary cirrhosis (PBC) improves biochemical liver tests, delays histological progression and prolongs survival without liver transplantation...
  22. Choi J, Kang J, Kim D, Sung Y, Lee S. Protective effects of Mg-CUD against D-galactosamine-induced hepatotoxicity in rats. Eur J Pharmacol. 2011;657:138-43 pubmed publisher
    ..chenoursodeoxycholic acid (Mg-CUD), a magnesium trihydrate salt of chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA), against D-galactosamine (D-GalN)-induced liver injury...
  23. Roma M, Toledo F, Boaglio A, Basiglio C, Crocenzi F, Sanchez Pozzi E. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011;121:523-44 pubmed publisher
    UDCA (ursodeoxycholic acid) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies. Its use has expanded to other kinds of hepatic diseases, and even to extrahepatic ones...
  24. Dalpiaz A, Paganetto G, Pavan B, Fogagnolo M, Medici A, Beggiato S, et al. Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system. Mol Pharm. 2012;9:957-68 pubmed publisher
    ..of zidovudine (AZT), an antiviral agent substrate of active efflux transport systems (AET), with ursodeoxycholic acid (UDCA), a bile acid able to permeate into the central nervous system (CNS)...
  25. Chun H, Low W. Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells. Toxicology. 2012;292:105-12 pubmed publisher
    Although ursodeoxycholic acid (UDCA) and its highly water-soluble formula (Yoo's solution; YS) have been shown to prevent neuronal damage, the effects of UDCA or YS against Parkinson's disease (PD)-related dopaminergic cell death has not ..
  26. Lee H, Jeong Y, Kim D, Kwak T, Chung C, Kim C, et al. Ursodeoxycholic acid-conjugated chitosan for photodynamic treatment of HuCC-T1 human cholangiocarcinoma cells. Int J Pharm. 2013;454:74-81 pubmed publisher
    Chitosan was hydrophobically modified with ursodeoxycholic acid (UDCA) to fabricate nano-photosensitizer for photodynamic therapy (PDT) of HuCC-T1 cholangiocarcinoma cells...
  27. Abbas G, Lindor K. Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert Opin Pharmacother. 2010;11:387-92 pubmed publisher
    ..Treatment with ursodeoxycholic acid has clearly improved the natural history of primary biliary cirrhosis...
  28. Levy C, Peter J, Nelson D, Keach J, Petz J, Cabrera R, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33:235-42 pubmed publisher
    Newer therapies are needed for patients with primary biliary cirrhosis and incomplete response to ursodeoxycholic acid (UDCA). Fenofibrate is a fibric acid postulated to regulate immune response and cell proliferation...
  29. Singh S, Khanna S, Pardi D, Loftus E, Talwalkar J. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19:1631-8 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) may modify the risk of inflammatory bowel disease (IBD)-associated colorectal cancer...
  30. Parry G, Rodrigues C, Aranha M, Hilbert S, Davey C, Kelkar P, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. 2010;33:17-21 pubmed publisher
    ..Neuronal cell death offers a potential target for therapeutic intervention. Ursodeoxycholic acid is a cytoprotective, endogenous bile acid that has been shown to be neuroprotective in experimental ..
  31. Zein C, Lindor K. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep. 2010;12:13-22 pubmed publisher
    ..In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with tangible biochemical, histologic, and survival benefits...
  32. Castro R, Ferreira D, Afonso M, Borralho P, Machado M, Cortez Pinto H, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58:119-25 pubmed publisher
    ..microRNA (miRNA or miR) expression has recently been reported to be altered in human NASH, and modulated by ursodeoxycholic acid (UDCA) in the rat liver...
  33. Myers R, Swain M, Lee S, Shaheen A, Burak K. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2013;108:933-41 pubmed publisher
    ..As ursodeoxycholic acid (UDCA) is not successful in all patients with primary biliary cirrhosis (PBC), additional treatment options ..
  34. Lee J, Gang G, Kim D, Kim Y, Koo S, Lee C, et al. Ursodeoxycholic acid inhibits liver X receptor ?-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. J Biol Chem. 2014;289:1079-91 pubmed publisher
    ..Furthermore, we investigated the mechanism by which ursodeoxycholic acid (UDCA) inhibits LXR-induced lipogenic gene expression...
  35. Chung G, Yoon J, Lee J, Kim H, Myung S, Yu S, et al. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncol Rep. 2011;25:1739-46 pubmed publisher
    b>Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, has been shown to inhibit mitogenic signaling and suppressing cell proliferation in colonic tumorigenesis...
  36. Song S, Liang J, Mulhern M, Madson C, Shinohara T. Cholesterol-derived bile acids enhance the chaperone activity of ?-crystallins. Cell Stress Chaperones. 2011;16:475-80 pubmed publisher
    ..We previously showed that two forms of the bile acid components--ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA)--suppressed lens epithelial cell death and alleviated cataract ..
  37. Wree A, Dechene A, Herzer K, Hilgard P, Syn W, Gerken G, et al. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84:54-9 pubmed publisher
    ..Treatment of severe DILI with corticosteroids (both pulse and step-down therapy) and UDCA appears to be safe, and leads to a more rapid reduction in bilirubin and transaminases after DILI. ..
  38. Kaya O, Ozdemir F, Atli M, Aslan V, Cağatay M, Anlar M, et al. The effects of ciprofloxacin and ursodeoxycholic acid on bacterial translocation in obstructive jaundice. Turk J Gastroenterol. 2009;20:186-91 pubmed
    ..to search the effects of two different drugs in bacterial translocation, both in combination and alone: ursodeoxycholic acid, the effectiveness of which was evidenced previously, and ciprofloxacin, which had not been used before, in ..
  39. Tsuda M, Moritoki Y, Lian Z, Zhang W, Yoshida K, Wakabayashi K, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012;55:512-21 pubmed publisher
    ..antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete response to ursodeoxycholic acid (UDCA)...
  40. Sokolovic D, Nikolic J, Kocic G, Jevtovic Stoimenov T, Veljkovic A, Stojanovic M, et al. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation. Drug Chem Toxicol. 2013;36:141-8 pubmed publisher
    ..b>Ursodeoxycholic acid (UDCA) acts as a protector in BA-induced cell injury...
  41. Imam M, Sinakos E, Gossard A, Kowdley K, Luketic V, Edwyn Harrison M, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:1185-92 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) in a dose of 28-30?mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients...
  42. Osorio H, Coronel I, Arellano A, Franco M, Escalante B, Bautista R. Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats. Diabetes Res Clin Pract. 2012;97:276-82 pubmed publisher
    ..Recent studies indicate that ursodeoxycholic acid (UDCA) may be beneficial preventing diabetes-induced oxidative stress and secondary complications...
  43. Wang S, Tang H, Chen G, Xu J, Zhong L, Wang Z, et al. Effect of ursodeoxycholic acid administration after liver transplantation on serum liver tests and biliary complications: a randomized clinical trial. Digestion. 2012;86:208-17 pubmed publisher
    ..This study was designed to investigate the effects of hydrophilic ursodeoxycholic acid (UDCA) administration early after OLT on serum liver tests and the incidence of biliary complications...
  44. Lim S, Duong H, Choi J, Lee T, Kang J, Oh S, et al. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis. 2011;32:723-31 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) is known as a suppressor of cholestatic liver diseases and colorectal cancer development...
  45. Hazzan R, Tur Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2010;44:371-3 pubmed publisher
    b>Ursodeoxycholic acid (UDCA) is the only current pharmacologic treatment for primary biliary cirrhosis (PBC). However, some patients show persistent liver biochemical abnormalities even after 6 to 12 months treatment...
  46. Lindstrom L, Boberg K, Wikman O, Friis Liby I, Hultcrantz R, Prytz H, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther. 2012;35:451-7 pubmed publisher
    ..b>Ursodeoxycholic acid (UDCA) has been suggested to have chemopreventive effects on the development of colorectal cancer and ..
  47. Xiang Z, Chen Y, Ma K, Ye Y, Zheng L, Yang Y, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140 pubmed publisher
    ..Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH...
  48. Zhou Y, Doyen R, Lichtenberger L. The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. Biochim Biophys Acta. 2009;1788:507-13 pubmed publisher
    ..However, ursodeoxycholic acid (UDC), a hydrophilic bile acid, is used to treat cholestasis because it protects membranes...
  49. Leuschner U, Lindenthal B, Herrmann G, Arnold J, Rossle M, Cordes H, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472-9 pubmed publisher
    In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using UDCA (13-15 mg/kg/day) was unable to confirm these results...
  50. Pietu F, Guillaud O, Walter T, Vallin M, Hervieu V, Scoazec J, et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol. 2012;36:146-55 pubmed publisher
    The combination of ursodeoxycholic acid (UDCA) and vitamin E is a therapeutic option for nonalcoholic steatohepatitis (NASH) but randomized controlled studies have produced inconsistent results...
  51. Sato S, Miyake T, Tobita H, Oshima N, Ishine J, Hanaoka T, et al. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World J Gastroenterol. 2009;15:2782-6 pubmed
    To examine whether a dose-up to 900 mg of ursodeoxycholic acid (UDCA) decreases transaminases in hepatitis C patients...
  52. Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136-41 pubmed publisher
    ..75% of the patients were treated with corticosteroids and showed a favorable response to treatment, whereas ursodeoxycholic acid was administered to 60% of the patients. The clinical features of patients with AIH in Japan were clarified...
  53. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009;7:239-45 pubmed publisher
    ..All patients were treated with ursodeoxycholic acid (UDCA); 9 with overlap syndrome also received immunosuppressants...